Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT).
about
Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis?Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT).The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT).Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials.Calcifications of vertebrobasilar arteries on CT: detailed distribution and relation to risk factors in 245 ischemic stroke patients.The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial.A previously unreported impact of a PLA2G7 gene polymorphism on the plasma levels of lipoprotein-associated phospholipase A2 activity and mass.A Link Between Hypoglycemia and Progression of Atherosclerosis in the Veterans Affairs Diabetes Trial (VADT).Cardiovascular metabolic syndrome: mediators involved in the pathophysiology from obesity to coronary heart disease.Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR.Is the risk and nature of CVD the same in type 1 and type 2 diabetes?Vascular calcification in diabetes: mechanisms and implications.Glucose targets for preventing diabetic kidney disease and its progression.Imaging Atherosclerosis in Diabetes: Current State.Basic fibroblast growth factor predicts cardiovascular disease occurrence in participants from the veterans affairs diabetes trialRelation of Risk Factors and Abdominal Aortic Calcium to Progression of Coronary Artery Calcium (from the Framingham Heart Study).Bone Mineral Density and Progression of Subclinical Atherosclerosis in African-Americans With Type 2 Diabetes.Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2.Relationship between HbA1c and risk of all-cause hospital admissions among people with Type 2 diabetes.Association of lipoprotein-associated phospholipase A2 mass with asymptomatic cerebral artery stenosis.Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study.EADSG Guidelines: Insulin Therapy in Diabetes.Quantification of abdominal aortic calcification: Inherent measurement errors in current computed tomography imaging.Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practiceDiabetes and Subclinical Coronary Atherosclerosis
P2860
Q36172927-D913F628-DC0F-46E0-AD46-9685ECB3C71CQ36334643-19076C94-BD59-4328-8546-68430FA6D5E6Q37022679-ED2618D9-27F4-4B91-AE9F-6F2C2B06FB65Q37023878-47429C41-9AA3-4AEA-B64C-AD918E78D268Q37104983-A084AF67-86F6-4072-B265-0EACFA94618FQ37170289-7419837F-3F1D-48BC-9D1B-969EC50DA3A4Q37460258-4DF77AA7-9CB6-47A7-86B8-55D55F2600A7Q37652806-1BB73E2A-C036-4AB5-BC4B-6102D237491FQ37980497-73D1586F-05C4-4F37-A468-BB726BC2E7DFQ38055296-5FCFF67E-A761-4B9E-A674-6BC786CE8EFCQ38092010-E3C95B33-1A75-4328-AFB6-E6F0730A80B8Q38092767-0937F3AC-EA2A-4C59-BA87-BC06C073521CQ38736800-5C56B0A5-1DF8-4FC5-969F-EC62A9839B39Q38818605-2DA5EC23-32D4-4608-858F-6B4150F4FC2BQ39298879-D5B6D094-55B6-458B-9E51-1674C6119318Q40228377-D1F5E440-FCE1-4C05-878F-0E498A287BA9Q40492905-4D4DBEE6-5D12-4047-B07C-4286DCBAF6FBQ42954976-2A8D7187-9E88-43C8-BB74-DDEE09FD427EQ43627828-DCBF5B6C-1495-4C8C-9FEE-48AB615E5FB4Q50102181-0D8DC9CF-3A1A-4427-983F-869F5750BFA9Q50598315-532A0554-82D7-4CED-A705-EC0A1467616DQ51245935-9AA80B09-29C3-4AE4-BDDE-DCA6195329F4Q52681393-90CE0011-4E80-4933-8B97-C112A3A05316Q58053312-94D305ED-8070-43A2-BF84-086712D46243Q58591197-2030FB3C-FB0C-44E3-8FC4-F28BFAECDF67
P2860
Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT).
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Rates and determinants of coro ...... Affairs Diabetes Trial (VADT).
@ast
Rates and determinants of coro ...... Affairs Diabetes Trial (VADT).
@en
Rates and determinants of coro ...... eterans Affairs Diabetes Trial
@nl
type
label
Rates and determinants of coro ...... Affairs Diabetes Trial (VADT).
@ast
Rates and determinants of coro ...... Affairs Diabetes Trial (VADT).
@en
Rates and determinants of coro ...... eterans Affairs Diabetes Trial
@nl
prefLabel
Rates and determinants of coro ...... Affairs Diabetes Trial (VADT).
@ast
Rates and determinants of coro ...... Affairs Diabetes Trial (VADT).
@en
Rates and determinants of coro ...... eterans Affairs Diabetes Trial
@nl
P2093
P2860
P356
P1433
P1476
Rates and determinants of coro ...... Affairs Diabetes Trial (VADT).
@en
P2093
Aramesh Saremi
Carlos Abraira
Peter D Reaven
Robert J Anderson
Thomas E Moritz
Veterans Affairs Diabetes Trial (VADT)
William C Duckworth
P2860
P304
P356
10.2337/DC10-1388
P407
P577
2010-08-31T00:00:00Z